Genzyme and Isis - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008 featuring Genzyme's $1.9 million partnership with Isis PharmaceuticalsWho: Genzyme
With: Isis Pharmaceuticals
What: $1.9B partnership

Summary: Genzyme forked out a hefty $1.9 billion to partner with Isis Pharmaceuticals on development of promising cardiovascular drug mipomersen. Isis got $375 million up front. Genzyme reportedly outbid 10 other companies for rights to the drug, which blocks a gene that opens the gate to cholesterol in the blood. The drug is now in multiple Phase III trials.

Genzyme and Isis - Top 10 deals of 2008
Read more on

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.